Medscape3d
FDA OKs Adjuvant Ribociclib in Earlier Stage Breast Cancer
The US Food and Drug Administration (FDA) approved ribociclib (Kisqali, Novartis) in combination with an aromatase inhibitor for adult patients with hormone receptor (HR)-positive, human epidermal ...
The American Journal of Managed Care5d
FDA Approves Ribociclib for Early Breast Cancer Treatment With High Recurrence Rate
The FDA approved ribociclib (Kisqali) for adjuvant treatment of high-risk, hormone receptor-positive, HER2-negative early breast cancer. The FDA approved ribociclib (Kisqali) with an aromatase ...
MedPage Today5d
FDA Expands Approval of Ribociclib to Early Breast Cancer
Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA on Tuesday approved ribociclib (Kisqali) in combination with endocrine therapy as adjuvant treatment for early ...
Indiatimes2d
Kisqali wins FDA nod for breast cancer treatment: Dosage, effectiveness and side effects of the breakthrough drug
The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It targets high-risk HR-positive, HER2-negative stage II and III patients ...
Yahoo Finance5d
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
Basel, September 17, 2024 – Novartis today announced that the US Food and Drug Administration (FDA) has approved Kisqali ® (ribociclib) in combination with an aromatase inhibitor (AI ...
AOL16d
Breast cancer drug could help prolong survival for children with brain tumors, study finds
A drug called ribociclib, currently used to treat breast cancer, could slow the progression of certain pediatric high-grade gliomas, an aggressive type of childhood brain cancer, a new study has ...
STAT4d
FDA awards Novartis expanded approval for breast cancer therapy
Kisqali, a key targeted therapy for breast cancer from Novartis, until now has been indicated only for patients with metastatic disease. But on Tuesday, the Food and Drug Administration approved ...
ascopubs.org26d
Targeted Therapies, Sequencing Strategies, and Beyond in Metastatic Hormone Receptor–Positive Breast Cancer: ASCO Guideline Clinical Insights
Fig 2. Summary of guideline recommendations. AEs, adverse events; CDK4/6, cyclin-dependent kinase 4/6; ESR1, estrogen receptor 2; ER, estrogen receptor; ET, endocrine ...
The American Journal of Managed Care23d
Novel Mechanisms Set FDA-Approved Amivantamab-Lazertinib Combo Apart in NSCLC
This newest approval for amivantamab is the second approval in 6 months for the EGFR and MET bispecific antibody. Data from the MARIPOSA study (NCT04487080) support this newest approval, and ...
oncnursingnews5d
FDA Approves Adjuvant Ribociclib Plus AI Therapy for HR+, HER2- Breast Cancer
The Food and Drug Administration approved ribociclib plus an aromatase inhibitor for hormone receptor (HR)–positive, HER2-negative stage II and III early breast cancer that has a high risk of ...
Targeted Oncology5d
FDA Approves Ribociclib With an Aromatase Inhibitor in Early Breast Cancer
Adjuvant ribociclib plus an aromatase inhibitor is now an FDA-approved treatment in HR-positive, HER2-negative stage II and III early breast cancer at a high risk of recurrence. The FDA has approved ...